SG10201505102WA - Treatment Of Cancer With TOR Kinase Inhibitors - Google Patents
Treatment Of Cancer With TOR Kinase InhibitorsInfo
- Publication number
- SG10201505102WA SG10201505102WA SG10201505102WA SG10201505102WA SG10201505102WA SG 10201505102W A SG10201505102W A SG 10201505102WA SG 10201505102W A SG10201505102W A SG 10201505102WA SG 10201505102W A SG10201505102W A SG 10201505102WA SG 10201505102W A SG10201505102W A SG 10201505102WA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- kinase inhibitors
- tor kinase
- tor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549034P | 2011-10-19 | 2011-10-19 | |
| US201261591401P | 2012-01-27 | 2012-01-27 | |
| US201261647233P | 2012-05-15 | 2012-05-15 | |
| US201261653436P | 2012-05-31 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201505102WA true SG10201505102WA (en) | 2015-07-30 |
Family
ID=47116477
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505102WA SG10201505102WA (en) | 2011-10-19 | 2012-10-18 | Treatment Of Cancer With TOR Kinase Inhibitors |
| SG10201912850WA SG10201912850WA (en) | 2011-10-19 | 2012-10-18 | Treatment Of Cancer With TOR Kinase Inhibitors |
| SG11201401630SA SG11201401630SA (en) | 2011-10-19 | 2012-10-18 | Treatment of cancer with tor kinase inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912850WA SG10201912850WA (en) | 2011-10-19 | 2012-10-18 | Treatment Of Cancer With TOR Kinase Inhibitors |
| SG11201401630SA SG11201401630SA (en) | 2011-10-19 | 2012-10-18 | Treatment of cancer with tor kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9493466B2 (ru) |
| EP (3) | EP3466423B1 (ru) |
| JP (5) | JP2014530861A (ru) |
| KR (1) | KR101978537B1 (ru) |
| CN (2) | CN103998036B (ru) |
| BR (1) | BR112014009755B1 (ru) |
| CA (1) | CA2852921C (ru) |
| EA (2) | EA030664B1 (ru) |
| ES (2) | ES2894958T3 (ru) |
| HK (1) | HK1243919A1 (ru) |
| IL (3) | IL232128B (ru) |
| IN (1) | IN2014CN02887A (ru) |
| MX (3) | MX357833B (ru) |
| MY (1) | MY183661A (ru) |
| SG (3) | SG10201505102WA (ru) |
| TW (4) | TWI758746B (ru) |
| UA (1) | UA115319C2 (ru) |
| WO (1) | WO2013059396A2 (ru) |
| ZA (2) | ZA201402771B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EP2945636B1 (en) | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| WO2014134240A1 (en) * | 2013-02-28 | 2014-09-04 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| KR102240356B1 (ko) * | 2013-04-17 | 2021-04-14 | 시그날 파마소티칼 엘엘씨 | Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법 |
| KR102271344B1 (ko) | 2013-04-17 | 2021-07-01 | 시그날 파마소티칼 엘엘씨 | 디하이드로피라지노-피라진을 사용한 암의 치료 |
| JP6382948B2 (ja) * | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
| AU2014254053B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Treatment of cancer with Dihydropyrazino-Pyrazines |
| KR102221005B1 (ko) * | 2013-04-17 | 2021-02-26 | 시그날 파마소티칼 엘엘씨 | 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법 |
| JP6389241B2 (ja) * | 2013-04-17 | 2018-09-12 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法 |
| NZ730189A (en) | 2013-04-17 | 2018-09-28 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| BR112015026021A2 (pt) * | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
| WO2014193912A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| EP3052093A1 (en) * | 2013-10-04 | 2016-08-10 | Signal Pharmaceuticals, LLC | A tor kinase inhibitor in the prevention or treatment of cancer characterized by gene mutations |
| WO2015160868A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| AU2016356694B2 (en) | 2015-11-20 | 2021-07-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| CN108602825A (zh) * | 2016-02-05 | 2018-09-28 | 中央研究院 | 具有抗癌活性的嘌呤化合物 |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| SI3558997T1 (sl) | 2016-12-20 | 2021-07-30 | Astrazeneca Ab | Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka |
| SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| AU2018360801A1 (en) * | 2017-11-01 | 2020-05-14 | Celgene Corporation | Process for producing a T cell composition |
| MX2020009372A (es) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
| CN110526907B (zh) * | 2018-05-23 | 2021-04-23 | 四川大学 | 苯并噁嗪酮类衍生物及其应用 |
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| US20230055321A1 (en) * | 2019-11-22 | 2023-02-23 | Medshine Discovery Inc. | Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors |
| KR20220106799A (ko) * | 2019-11-25 | 2022-07-29 | 메드샤인 디스커버리 아이엔씨. | Dna-pk 억제제로서의 피리미도이미다졸계 화합물 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE262026C (ru) | ||||
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
| US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
| US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
| US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
| US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
| GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法 |
| DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
| TW274550B (ru) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
| US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| DK1017384T3 (da) | 1997-09-26 | 2005-01-31 | Zentaris Gmbh | Azabenzimidazolbaserede forbindelser til modulation af serin/threoninproteinkinasefunktion |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬 |
| JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
| JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体 |
| ES2249384T3 (es) | 2000-12-12 | 2006-04-01 | Neurogen Corporation | Espiro(isobenzofuran-1,4'-piperadin)-3-onas y 3h-espirobenzofuran-1,4-piperidinas. |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| UY27427A1 (es) | 2001-09-04 | 2003-03-31 | Boehringer Ingelheim Pharma | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos |
| JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物 |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| NZ536123A (en) | 2002-05-06 | 2006-09-29 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
| US20040204420A1 (en) | 2002-08-05 | 2004-10-14 | Rana Tariq M. | Compounds for modulating RNA interference |
| JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| PT1599478E (pt) | 2003-02-26 | 2007-05-31 | Boehringer Ingelheim Pharma | Di-hidropteridinonas, proceso para a sua preparação e a sua utilização como medicamento |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| US20040213757A1 (en) * | 2003-04-23 | 2004-10-28 | Wyeth Holdings Corporation | Water soluble wortmannin derivatives |
| CN100503628C (zh) | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
| US7476665B2 (en) | 2003-06-26 | 2009-01-13 | Merck & Co., Inc. | Benzodiazepine CGRP receptor antagonists |
| WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | ２－アリールプリン誘導体の製造方法 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7608622B2 (en) * | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases |
| MX2007005159A (es) | 2004-10-29 | 2007-06-26 | Tibotec Pharm Ltd | Derivados de pirimidina biciclicos inhibidores del vih. |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
| AU2005316668B2 (en) | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| ES2308731T3 (es) | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | Compuestos quimicos. |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| RU2007140903A (ru) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
| KR20080071600A (ko) | 2005-11-21 | 2008-08-04 | 노파르티스 아게 | Ｍｔｏｒ 억제제를 사용하는 신경내분비 종양 치료법 |
| US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| ES2558517T3 (es) * | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
| US20100144738A1 (en) | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
| AU2007338601C1 (en) | 2006-09-05 | 2014-07-24 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| ES2381215T3 (es) | 2006-10-19 | 2012-05-24 | Signal Pharmaceuticals Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
| AU2007309468B2 (en) | 2006-10-19 | 2012-05-17 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2010056311A1 (en) | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| JP5930278B2 (ja) | 2008-11-25 | 2016-06-08 | ユニバーシティー オブ ロチェスター | Ｍｌｋ阻害剤および使用方法 |
| WO2011053518A1 (en) | 2009-10-26 | 2011-05-05 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
| EP2531194B1 (en) | 2010-02-03 | 2018-04-18 | Signal Pharmaceuticals, LLC | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| US20120028972A1 (en) | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
| WO2013019927A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| SG10201604558SA (en) | 2011-12-02 | 2016-07-28 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4 methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
-
2012
- 2012-10-18 EP EP18207204.1A patent/EP3466423B1/en active Active
- 2012-10-18 MX MX2017002007A patent/MX357833B/es unknown
- 2012-10-18 TW TW109119519A patent/TWI758746B/zh active
- 2012-10-18 SG SG10201505102WA patent/SG10201505102WA/en unknown
- 2012-10-18 EP EP20152170.5A patent/EP3659599B1/en active Active
- 2012-10-18 KR KR1020147012908A patent/KR101978537B1/ko active IP Right Grant
- 2012-10-18 ES ES18207204T patent/ES2894958T3/es active Active
- 2012-10-18 CN CN201280062920.5A patent/CN103998036B/zh active Active
- 2012-10-18 UA UAA201405225A patent/UA115319C2/uk unknown
- 2012-10-18 JP JP2014537216A patent/JP2014530861A/ja active Pending
- 2012-10-18 TW TW101138515A patent/TWI629983B/zh active
- 2012-10-18 CA CA2852921A patent/CA2852921C/en active Active
- 2012-10-18 US US13/654,441 patent/US9493466B2/en active Active
- 2012-10-18 SG SG10201912850WA patent/SG10201912850WA/en unknown
- 2012-10-18 IN IN2887CHN2014 patent/IN2014CN02887A/en unknown
- 2012-10-18 CN CN201710320646.1A patent/CN107157990B/zh active Active
- 2012-10-18 SG SG11201401630SA patent/SG11201401630SA/en unknown
- 2012-10-18 TW TW106118908A patent/TWI708605B/zh active
- 2012-10-18 BR BR112014009755-0A patent/BR112014009755B1/pt active IP Right Grant
- 2012-10-18 ES ES12780374T patent/ES2751921T3/es active Active
- 2012-10-18 MY MYPI2017000252A patent/MY183661A/en unknown
- 2012-10-18 WO PCT/US2012/060723 patent/WO2013059396A2/en active Application Filing
- 2012-10-18 TW TW106118909A patent/TWI713752B/zh active
- 2012-10-18 MX MX2014004775A patent/MX348566B/es active IP Right Grant
- 2012-10-18 EA EA201490814A patent/EA030664B1/ru not_active IP Right Cessation
- 2012-10-18 MX MX2020004689A patent/MX2020004689A/es unknown
- 2012-10-18 EP EP12780374.0A patent/EP2768500B1/en active Active
- 2012-10-18 EA EA201890768A patent/EA034512B1/ru not_active IP Right Cessation
-
2014
- 2014-04-13 IL IL232128A patent/IL232128B/en active IP Right Grant
- 2014-04-15 ZA ZA2014/02771A patent/ZA201402771B/en unknown
- 2014-10-24 ZA ZA2014/07793A patent/ZA201407793B/en unknown
-
2016
- 2016-09-27 US US15/277,285 patent/US9937170B2/en active Active
- 2016-12-02 JP JP2016234951A patent/JP6360136B2/ja active Active
-
2018
- 2018-01-10 IL IL256828A patent/IL256828B/en active IP Right Grant
- 2018-02-20 US US15/899,706 patent/US11166950B2/en active Active
- 2018-03-09 HK HK18103366.0A patent/HK1243919A1/zh unknown
- 2018-06-21 JP JP2018117932A patent/JP2018162286A/ja active Pending
-
2020
- 2020-07-07 JP JP2020117028A patent/JP2020169203A/ja active Pending
-
2021
- 2021-03-01 IL IL281180A patent/IL281180B2/en unknown
- 2021-05-06 JP JP2021078559A patent/JP2021107461A/ja active Pending
- 2021-10-07 US US17/496,433 patent/US20220273650A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| EP2760452A4 (en) | METHODS OF TREATING CANCER | |
| HK1202253A1 (en) | Combination treatment of cancer | |
| HK1202240A1 (en) | Methods of treating cancer | |
| ZA201503105B (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| IL228430A0 (en) | Cancer treatment | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors | |
| IL232266A0 (en) | Cancer treatment methods | |
| GB201121783D0 (en) | Treatment of cancer | |
| GB201121791D0 (en) | Combination treatment of cancer |